US

Biogen CEO Christopher Viehbacher commented during the company’s first quarter earnings call that they are not worried about competing with Eli Lilly in the market for Alzheimer’s drugs. Both companies are working toward bringing their respective drugs to the market, with Biogen and Japanese drugmaker Eisai developing leqembi, and Eli Lilly developing donanemab and remternetug.
General Motors (GM) is set to release its first-quarter earnings on Tuesday, and according to the Refinitiv consensus estimates, adjusted earnings per share are expected to be $1.73 with revenue of $38.95 billion. While this would mark a significant decline in adjusted EPS from last year, it would represent an 8.3% increase in revenue as